PMID- 38061494
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240401
IS  - 2213-5383 (Electronic)
IS  - 2213-5383 (Linking)
VI  - 39
DP  - 2024 Mar
TI  - Use of subjective minimizing language at hematology and oncology conferences: A 
      systematic review.
PG  - 100461
LID - S2213-5383(23)00078-4 [pii]
LID - 10.1016/j.jcpo.2023.100461 [doi]
AB  - BACKGROUND: Subjective minimizing language in oncology conferences may undermine 
      patient-centered care and hinder comprehensive treatment strategies. Subjective 
      terms like "safe," "tolerable," and "well-tolerated" can vary in interpretation 
      among individuals, making it difficult to compare results across trials and 
      potentially downplaying significant risks and limitations associated with 
      treatments. METHODS: This study evaluates subjective minimizing language in major 
      oncology conferences and its use in adverse event reporting. We conducted a 
      search of three electronic databases, ASCO, ASH, and ESMO, for published 
      abstracts from January 1, 2019, to December 31, 2021. This study included 
      prospective cohort studies or clinical trials in humans that used safety terms 
      like "safe," "well-tolerated," "tolerable," "no new safety signal," or "no new 
      safety concern" in the abstract text. RESULTS: Out of 34,975 reviewed records, 
      5299 (15.2%) abstracts used subjective minimizing language terms. The analysis 
      included 2797 (52.8%) abstracts meeting the inclusion criteria. The majority of 
      studies were Phase 1 trials (45.5%), followed by Phase 2 (29.6%) and Phase 3 
      trials (7.4%). Solid tumors accounted for the most common disease category 
      (56.5%), followed by malignant hematology following (37.1%). Subjective 
      minimizing terms like "safe" (69.2%), "well-tolerated" (53.2%), "tolerable" 
      (25.6%), and "no new safety signal/concerns" (10%) were used frequently. Of the 
      abstracts using subjective minimizing language (n = 2797), 81.9% reported data on 
      any grade adverse events (AEs). Grade I/II AEs were reported in 62.6% of 
      abstracts, Grade III/IV AEs in 78%, and Grade V AEs (death related to AEs) in 
      8.8%. Discontinuation due to AEs occurred in 11.4% (SD 9.5%) of studies using 
      subjective minimizing language terms. CONCLUSIONS: Frequent use of subjective 
      minimizing language in major oncology conferences' abstracts may obscure 
      interpretation of study results and the safety of novel treatments. Researchers 
      and clinicians should provide precise and standardized information to avoid 
      overstatement of benefits and understand the true impact of interventions on 
      patients' safety and well-being.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Abusamak, Abdel-Azez
AU  - Abusamak AA
AD  - Department of Internal Medicine, Rutgers Health, RWJ Trinitas Regional Medical 
      Center, Elizabeth, NJ, USA.
FAU - Abusamak, Mohammad
AU  - Abusamak M
AD  - Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, 
      QC, Canada.
FAU - Al-Abbadi, Mohammed
AU  - Al-Abbadi M
AD  - School of Medicine, University of Jordan, Amman, Jordan.
FAU - Rayyan, Abdallah
AU  - Rayyan A
AD  - School of Medicine, University of Jordan, Amman, Jordan.
FAU - Oran, Omar
AU  - Oran O
AD  - School of Medicine, University of Jordan, Amman, Jordan.
FAU - Mohyuddin, Ghulam Rehman
AU  - Mohyuddin GR
AD  - University of Utah, Salt Lake City, UT, USA.
FAU - Kelkar, Amar H
AU  - Kelkar AH
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 
      Harvard Medical School, Boston, MA, USA.
FAU - Goodman, Aaron M
AU  - Goodman AM
AD  - University of California San Diego, La Jolla, CA, USA.
FAU - Chakraborty, Rajshekhar
AU  - Chakraborty R
AD  - Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical 
      Center, New York, NY, USA.
FAU - Cliff, Edward R Scheffer
AU  - Cliff ERS
AD  - Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and 
      Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, 
      MA, USA.
FAU - Al Hadidi, Samer
AU  - Al Hadidi S
AD  - Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas 
      for Medical Sciences, Little Rock, AR, USA. Electronic address: 
      salhadidi@uams.edu.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20231205
PL  - England
TA  - J Cancer Policy
JT  - Journal of cancer policy
JID - 101639933
SB  - IM
MH  - Humans
MH  - *Neoplasms/therapy
MH  - Prospective Studies
MH  - *Hematology
MH  - *Medical Oncology
MH  - *Terminology as Topic
OTO - NOTNLM
OT  - Adverse events
OT  - Cancer
OT  - Oncology
OT  - Subjective minimizing language
OT  - Well-tolerated
COIS- Declaration of Competing Interest A.A., M.A., M.A.A., A.R.,O.O, G.R.M, A.H.K, 
      A.M.G and R.C. reported no conflict of interest. ERSC receives research funding 
      from Arnold Ventures. S.A. reported receiving honoraria from Janssen and Sanofi.
EDAT- 2023/12/08 00:41
MHDA- 2024/03/08 06:43
CRDT- 2023/12/07 19:25
PHST- 2023/10/20 00:00 [received]
PHST- 2023/12/03 00:00 [accepted]
PHST- 2024/03/08 06:43 [medline]
PHST- 2023/12/08 00:41 [pubmed]
PHST- 2023/12/07 19:25 [entrez]
AID - S2213-5383(23)00078-4 [pii]
AID - 10.1016/j.jcpo.2023.100461 [doi]
PST - ppublish
SO  - J Cancer Policy. 2024 Mar;39:100461. doi: 10.1016/j.jcpo.2023.100461. Epub 2023 
      Dec 5.